Proteomic identification of a marker signature for MAPKi resistance in melanoma

MAPK inhibitors (MAPKi) show outstanding clinical response rates in melanoma patients harbouring BRAF mutations, but resistance is common. The ability of melanoma cells to switch from melanocytic to mesenchymal phenotypes appears to be associated with therapeutic resistance. High‐throughput, subcell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO J
Main Authors: Paulitschke, Verena, Eichhoff, Ossia, Gerner, Christopher, Paulitschke, Philipp, Bileck, Andrea, Mohr, Thomas, Cheng, Phil F, Leitner, Alexander, Guenova, Emmanuella, Saulite, Ieva, Freiberger, Sandra N, Irmisch, Anja, Knapp, Bernhard, Zila, Nina, Chatziisaak, Theodora‐Pagona, Stephan, Jürgen, Mangana, Joanna, Kunstfeld, Rainer, Pehamberger, Hubert, Aebersold, Ruedi, Dummer, Reinhard, Levesque, Mitchell P
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6669927/
https://ncbi.nlm.nih.gov/pubmed/31267558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201695874
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados